Galectin Therapeutics Inc.
GALTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The $186.0M market capitalization puts GALT squarely in micro-cap range for its industry. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Market Cap
$186.0M
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
-1.68
EPS (TTM)
$-0.41
EPS (Fwd)
$-1.68
ROE
—
ROA
-80.4%
Cash
$14.1M
Total Debt
$138.7M
Free CF
-$18.7M
52W Change
16.9%
Annual Financials
Cash vs Debt
Galectin Therapeutics Inc. carries $138.7M in total debt against $14.1M in cash reserves — debt is roughly 9.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$18.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The relatively low beta of 0.49 suggests GALT is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing GALT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.